Results 71 to 80 of about 136,268 (220)

Humanization of Pan-HLA-DR mAb 44H10 Hinges on Critical Residues in the Antibody Framework

Antibodies
Reducing the immunogenicity of animal-derived monoclonal antibodies (mAbs) for use in humans is critical to maximize therapeutic effectiveness and preclude potential adverse events.
Audrey Kassardjian, Danton Ivanochko, Brian Barber, Arif Jetha, Jean-Philippe Julien   +4 more
doaj   +1 more source

Tumor‐Derived Alpha‐1 Antitrypsin Promotes Liver Metastasis of Colorectal Cancer Through the Neutrophil Extracellular Traps–CCDC25 Pathway

Advanced Science, EarlyView.
ABSTRACT Liver metastasis is a leading cause of mortality in colorectal cancer (CRC), where the inflammatory tumor microenvironment, specifically neutrophil infiltration, significantly promotes metastatic colonization. This study reveals a pro‐metastatic role for alpha‐1 antitrypsin (A1AT) in CRC liver metastasis via a dual mechanism involving ...
Qian Fei, Chunning Li, Lei Zhan, Xiaoyan Li, Yan Hui, Yue Jin, Jing Zhang, Lu Yang, Xin Sun, Xiaoxi Li, Qian Dong, Jingdong Zhang   +11 more
wiley   +1 more source

Quantitative Mass Spectrometry‐Based Biodistribution of Monoclonal Antibodies: An Alternative to Radio‐Biodistribution

Advanced Science, EarlyView.
Monoclonal antibodies are powerful anticancer therapeutics targeting tumor‐associated antigens. Mass spectrometry enables precise and accurate quantification of mAbs in tumor plasma and healthy organs. Unlike ligand binding assay and radioactivity, mass spectrometry does not suffer from matrix effects and labelling artefacts while facilitating method ...
Domenico Ravazza, Sheila Dakhel Plaza, Samuele Cazzamalli, Andrea Ciamarone, Andrea Galbiati, Riccardo Stucchi, Frederik Peissert, Emanuele Puca, Dario Neri, Ettore Gilardoni   +9 more
wiley   +1 more source

A novel fully human anti-ROR1 antibody PBA-0405 optimized for ADCC, induces potent anti-tumor activity against both solid and hematological malignancies

Frontiers in Immunology
IntroductionB-cell malignancies, including chronic lymphocytic leukemia (CLL), pose a significant clinical challenge due to high relapse rates and dose-limiting toxicities seen with current therapies, particularly in elderly patients.
Niina Veitonmäki, Anna Kostyn, Sonia Kołt, Aleksandra Ziemblicka, Beata Romanowska, Sabina Oleksy, Ewelina Krzywińska, Kamilla Sołtys, Łukasz Świderski, Piotr Naporowski, Piotr Mamczur, Monika Świtoń, Marek Orłowski, Marek Orłowski, Ying Zhang, Jianming Xu, Anna Andrzejczak, Aleksandra Bielawska-Pohl, Lidia Karabon, Dariusz Wołowiec, Wondossen Sime, Ramin Massoumi, Sameer Deshmukh, Jakub Kołodziejski, Tomasz Klaus, Pieter Spee   +25 more
doaj   +1 more source

Macrophage Extracellular Traps in Immunity and Cancer

Advanced Science, EarlyView.
As a macrophage‐mediated innate defense mechanism, the dysregulated release of METs drives chronic inflammation and influences tumor progression. Furthermore, METs exhibit a functional duality within the tumor microenvironment, capable of both promoting and suppressing tumor development.
Junyao Li, Eugenie Nepovimova, Adam Grundel, Lukas Peter, Qinghua Wu, Kamil Kuca   +5 more
wiley   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Rapid production of monoclonal antibodies from single mouse B cells against FMDV

Animal Diseases
Single B-cell antibody generation technology is an advanced method that offers several advantages, including rapid production, high efficiency, and high yield.
Zhengxin Yang, Fangtao Li, Mengjia Zhang, Yan Li, Qizu Zhao, Chunyan Wang, Lu Xu, Yebing Liu, Wentao Li, Yuanyuan Zhu   +9 more
doaj   +1 more source

Selective Targeting of Immune Checkpoints HLA‐G and CD47 Using Novel Dual Signaling Protein DSP216 Promotes Innate Anticancer Immunity

Advanced Science, EarlyView.
The inhibitory immune checkpoints HLA‐G and CD47 are expressed on certain tumor types and inhibit immune cells in the tumor microenvironment. DSP216 binds specifically to cancer cells expressing both HLA‐G and CD47, and blocks their inhibitory signaling.
Lisa J. Jacob, Liat Tamir, Mufeed Abdeen, Ami Tamir, Alexandra Aronin, Itai Bloch, Roy Kahn, Iris Pecker, Mark Tykocinski, Gerwin Huls, Yaron Pereg, Ayelet Chajut, Edwin Bremer   +12 more
wiley   +1 more source

Tumor‐Derived Exosomes Deliver Membrane‐Bound Fgl2 to Activate FcγRIIB‐Mediated Immunosuppression in Myeloid‐Derived Suppressor Cells

Advanced Science, EarlyView.
This study reveals that the Fgl2‐FcγRIIB signaling axis is a key mechanism by which MDSCs mediate tumor immune evasion. Tumor‐derived exosomes systemically activate MDSCs via this pathway, positioning this axis as a promising broad‐spectrum target for cancer immunotherapy.
Fenglin Lin, Dingqin Cai, Chunli Jian, Yaxian Qi, Linpeng Zheng, Qiao Yang, Longyao Zhang, Diangang Chen, Lingchen Li, Ping Cai, Lingyou Sun, Luping Zhang, Jianguo Sun   +12 more
wiley   +1 more source

Inhibition of HER2 signaling and breast cancer cell growth with a novel antibody targeting HER2 ECD III/IV.

PLoS ONE
Human epidermal growth factor receptor 2 (HER2), a ligand-independent tyrosine kinase receptor belonging to the EGFR family, serves as a key oncogenic driver in breast, gastric, and several other solid tumors.
Chunchun Liu, Yulei Ren, Xuan Luo, Peiyun Zhou, Xiangjuan Du, Qianmin Wang, Xue Han, Yanhui Xu, Ping Wang, Dan Zhao, Huirong Yang   +10 more
doaj   +1 more source